A Personal Health App and Wearable Co-Design Framework for Rare and Complex Diseases: User-Centered, Collaborative Co-Design Study.

Publication date: Jul 20, 2026

End user co-design in the personal digital health technology space is underdeveloped. Clinical uptake of personal digital health technologies has been poor, highlighting a need to cocreate solutions with end users. The study aimed to describe an “end user” co-design framework in the development of 5 prototype personal health apps for patients with different rare or complex diseases. A patient-led, user-centered, collaborative personal health app plus wearable plug-in co-design methodology was developed. Five prototype apps were developed for end users with long COVID-19, pancreatitis, primary ciliary dyskinesia, sarcoidosis, and valosin-containing protein disease by a multidisciplinary partnership including patients, app design and development experts, user experience experts, clinicians, and patient-driven organizations. Phase 1 involved a 6-month co-design process with 5 modules involving patient-driven organizations that included the codevelopment of specifications through group workshops and independent exercises that defined the goals, content, features, and user experience of each app. Phase 2 involved app build-out, internal alpha testing, and beta study preparations. Phase 3 involved a usability beta testing study in which end users used the app and associated wearable/smart devices (Oura ring, Lumia ear device, Empatica EmbracePlus, and MIR Spirobank Spirometer) for up to 5 months. Participant feedback was documented continuously and systematically, centering on the following themes: functionality, usability, harms, benefits, self-explorations, and beta testing study details related to retention and adherence. While unique app goals were codeveloped by each disease group, a central goal across groups was to develop a personal health app enabling users to track subjective, self-reported symptoms, objective measures of health, and unique modifiers of symptoms. A total of 239 end user participants participated in the beta testing pilot study. Enrollment and retention rates were high, ranging from 94% to 100% and 92. 2% to 100%, respectively. All active participants gave some form of feedback: there were 257 unique participant suggestions of how to specifically modify or improve the study app experience. Participant feedback themes commonly centered around customization to reduce daily burden and improve personal tailoring of the app. Participants’ desires surrounding symptom displays were heterogeneous. Personal health app co-design is rooted in a complex digital landscape that requires a significant amount of up-front effort and time. However, the up-front investment of time can result in rich and diverse end user feedback that could save time in the app development trajectory to implementation. This paper provides a co-design framework and the building blocks of 5 prototype personal health apps with publicly available open-source code on GitHub. These prototypes could be leveraged for improving understanding of, communicating symptoms of, and providing n-of-1 suggestions for rare or complex diseases, providing benefit to patient communities and individual patients.

Open Access PDF

Concepts Keywords
co-design
COVID-19
Digital Health
digital health
Female
Humans
l ong COVID-19
Male
Mobile Applications
mobile health
pancreatitis
PCD
primary ciliary dyskinesia
Rare Diseases
sarcoidosis
SARS-CoV-2
Telemedicine
user-centered
User-Centered Design
valosin-containing protein
VCP disease
Wearable Electronic Devices
wearables

Semantics

Type Source Name
disease MESH pancreatitis
disease MESH primary ciliary dyskinesia
disease MESH sarcoidosis
disease MESH included
drug DRUGBANK Methylphenidate
drug DRUGBANK Morpholinylmercaptobenzothiazole
disease MESH MBS
disease MESH MHA
disease MESH PCD
disease MESH long COVID
disease MESH COVID 19
drug DRUGBANK Oxygen
disease MESH fatigue
disease MESH chronic illnesses
drug DRUGBANK Stanolone
drug DRUGBANK Isoxaflutole
disease MESH obesity
disease MESH dementia
drug DRUGBANK Aspartame
drug DRUGBANK Spinosad
drug DRUGBANK Methyltestosterone
disease MESH anxiety
disease MESH injuries
disease MESH EDA
disease MESH pain
disease MESH dysautonomia
drug DRUGBANK Etoperidone
disease MESH visual impairments
disease MESH contact dermatitis
disease MESH Rare Diseases

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *